By Arasu Kannagi Basil (Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial public offering, set to be the first U.S.

(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...

Killer Burger, the Portland, Oregon-based chain, known for its peanut butter-pickle-bacon burger, has a new CEO. Adam Sanders ...

Not all cruise cabins are created equal. There are at least five types of staterooms I will be avoiding from now on. I’ve ...

Despite Eastwood’s track record of commercial success (his films have grossed around $9 billion for the studio), Juror #2 received a limited US theatrical release in just 46 theatres before its ...

Increasingly more “post” than “black,” this album encapsulates the best tenets of Harakiri for the Sky, in pursuit of ...

Florham Park, N.J.-based Conduent—whose systems are used to enable government services such as child support payments and ...

Kevin Brown, who had been CEO since 2003, will transition to executive chairman. R.J. Melman had been president of the ...

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

California Insurance Commissioner Ricardo Lara discusses the complex insurance system as homeowners look to rebuild after ...

The New Orleans Jazz & Heritage Festival has announced the loaded artist lineup for its 2025 edition in April and May.